6-Methoxyflavone induces S-phase arrest through the CCNA2/CDK2/p21CIP1 signaling pathway in HeLa cells

Chaihong Zhang a,b, Yuchong Quan a, Lijuan Yang a,b, Yingying Bai a,b and Yongxiu Yang a,b,d

a The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, China; b Key Laboratory of Gynecological Oncology of Gansu Province, Lanzhou, Gansu, China; c College of Basic Medicine, Dalian Medical University, Dalian, Liaoning, China; d Department of Obstetrics and Gynecology, First Hospital of Lanzhou University, Lanzhou, Gansu, China

ABSTRACT
This study aimed to elucidate the specific anticancer mechanism of 6-methoxyflavone in HeLa cells. A total of 178 putative targets of 6-methoxyflavone were obtained from the PharmMapper database. Microarray analyses, transcriptome sequencing analyses, functional enrichment analyses, and gene set enrichment analyses were performed to preliminarily explore the roles and mechanisms of the 178 targets in cervical cancer. Cell counting kit-8, cell cycle assays, polymerase chain reactions, and western blotting were used to clarify the mechanism of action of 6-methoxyflavone. Molecular docking and noncovalent interaction analyses were performed to further confirm the mechanism of action in three-dimensional structures. Functional enrichment analyses and gene set enrichment analyses indicated that high mRNA expression of cyclin A2 (CCNA2) and cyclin-dependent kinase 2 (CDK2) stimulated cell cycle progression in cervical cancer. Cell proliferation and cycle assays, transcriptome sequencing, polymerase chain reactions, and western blotting revealed that 6-methoxyflavone inhibited HeLa cell proliferation and induced S-phase arrest via the CCNA2/CDK2/cyclin-dependent kinase inhibitor 1A (p21CIP1) pathway. Molecular docking and noncovalent interaction analyses showed that 6-methoxyflavone had the strongest affinity toward, inhibitory effect on, and noncovalent interactions with CDK2, and that the combination of CDK2 and CCNA2 enhanced these effects. An analysis of clinical characteristics showed that 6-methoxyflavone might be related to six clinicopathological parameters of cervical cancer patients. 6-Methoxyflavone induces S-phase arrest in HeLa cells via the CCNA2/CDK2/p21CIP1 pathway.

KEYWORDS
6-methoxyflavone; cell cycle; cervical cancer; network pharmacology; molecular docking
Introduction

Cervical cancer, including cervical adenocarcinoma, is a prominent threat to the health of women. The incidence [1], therapeutic tolerance rate [2], recurrence rate [3], probability of pelvic lymph node involvement [4], possibility of ovarian invasion [5] and distant metastasis rate [6] of cervical adenocarcinoma remain high. Chemotherapy is an important complement to surgical treatment for cervical cancer. However, there are still challenges regarding drug sensitivity, targeting, toxicity, and resistance. Hence, low-toxicity and high-sensitivity drugs and in-depth studies of their mechanisms of action are urgently needed.

Various Chinese herbal decoctions have been used to treat tumors for thousands of years. Plant-derived anticancer drugs such as paclitaxel, camptothecin series, podophyllotoxin, harringtonine, and turmeric extract have been approved for commercial sale for decades. Traditional Chinese medicine and its active ingredients have an increasingly important role in cancer treatment. 6-Methoxyflavone is derived from the Chinese herbal medicine Imperata Cylindrica and is an effective ingredient of Imperatae rhizoma. Previous studies of 6-methoxyflavone have shown a wide range of allosteric modulatory effects [7], immunological regulation effects [8], antiproliferation and anticancer effects [9], antinociceptive effects [10], and anti-inflammatory effects [11]. A chemotherapeutic drug screening study confirmed that 6-methoxyflavone has an inhibitory effect on HeLa cells [9]. Although an anticancer effect of 6-methoxyflavone on HeLa cells was previously observed, the specific mechanism of action has not been described.

During this study, we aimed to explore the potential role of 6-methoxyflavone in HeLa cells. First, microarray analyses, transcriptome sequencing analyses, functional enrichment analyses, and gene set enrichment analyses were performed to clarify the roles of 6-methoxyflavone in the cervical cancer cell cycle. Cell cycle assays further indicated that 6-methoxyflavone markedly induced S-phase arrest. Furthermore, transcriptome sequencing, polymerase chain reactions, western blotting, molecular docking, and noncovalent interaction analyses were used to clarify the mechanism of action of 6-methoxyflavone, and it was discovered that 6-methoxyflavone markedly induced S-phase arrest via the cyclin A2 (CCNA2)/cyclin-dependent kinase 2 (CDK2)/cyclin-dependent kinase inhibitor 1A (p21CIP1) pathway in HeLa cells.

Materials and methods

There were no ethical issues involved in this study.

Putative targets of 6-methoxyflavone

The three-dimensional conformer of 6-methoxyflavone was downloaded from the PubChem database [12]. The putative targets of 6-methoxyflavone were obtained from the PharmMapper database [13–15]. Only the human protein target set (version 2010) was selected. Finally, we identified 178 human protein targets of 6-methoxyflavone.

Functional enrichment analysis

The 178 targets of 6-methoxyflavone were used for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses of the DAVID database (version 6.8) [16,17]. We used a threshold of p < 0.05 to filter the items downloaded from DAVID. Finally, we used GraphPad Prism 8.0.1 (https://www.graphpad.com/scientific-software/prism/), the GOplot package [18] of R 4.1.2 (https://www.r-project.org/), and the Jvenn online tool [19] to visualize the enrichment items of the targets.

Microarray analysis

The raw data of mRNA expression and clinical characteristics of 304 cervical cancer samples and three healthy cervical samples were downloaded from The Cancer Genome Atlas database (http://cancergenome.nih.gov/). We used Perl 5.30.3 (https://www.perl.org/) to identify mRNAs and lncRNAs. We used the R package edgeR [20] to export the mRNA expression profiles of cervical cancer cases and identified differentially
expressed mRNAs (DEmRNAs) in cancer tissues and healthy tissues. The thresholds of \(|\log_2 \text{ fold change}|\) and the adjusted p value were set as 1.0 and 0.05, respectively. GraphPad Prism was used to statistically analyze clinical data. The Jvenn online database was used to visualize the intersection between the targets and DEmRNAs.

**Gene set enrichment analysis**

A gene set enrichment analysis was performed to explore the functions of intersecting genes in cervical cancer. First, we obtained the expression data of the intersecting genes identified in the mRNA expression profile of cervical cancer. Then, we extracted the expression data of the intersecting genes from the profiles. We divided the intersecting genes into high-expression and low-expression groups using the median method and generated a phenotype data file. Finally, the two files were evaluated using gene set enrichment analysis version 4.0.3 [21,22], the website’s gene matrix, and signal2noise method. Significant terms with \(q < 0.01\) were selected. These terms were ranked within each dataset according to the normalized enrichment score. GraphPad Prism and the ggplot2 R package [23] were used to visualize the results.

**Transcriptome sequencing**

After HeLa cells were cultured with 0.16% dimethyl sulfoxide (DMSO) and 65 \(\mu\)M 6-methoxyflavone for 48 hours, the total RNA extraction reagent (Takara, Dalian, China) was applied to lyse the cells on ice [24]. RNA libraries were constructed, and transcriptome sequencing was performed using an Illumina Hiseq\textsuperscript{TM} platform (Illumina Inc., San Diego, CA, USA) at Sangon Biotech Co., Ltd. (Shanghai, China). High-throughput sequencing data quality control and genomic contamination were assessed using FastQC version 0.11.2 software (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Differentially expressed transcripts were identified as \(\geq 5\) transcripts per million, an absolute value of \(\log_2 \text{ fold change} >1\), and \(q < 0.05\). Pathways and biological process enrichment analyses were performed and visualized using the KEGG, DAVID databases, and GraphPad Prism version 8.0.1 for Windows.

**Small molecule compound and cell culture**

6-Methoxyflavone (CAS: 26,964–24-9) was obtained from Weikeqi Biological Technology Co., Ltd. (Chengdu, China). The compound powder was dissolved in DMSO under ultrasonic oscillation. Human cervical cancer cell lines (HeLa, C33A, and SiHa) and a human immortal keratinocyte line (HaCaT) were obtained from the Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences (Beijing, China). The cells were seeded in treated tissue culture plates or flasks (25 cm\(^2\)) in modified Eagle's medium or Dulbecco's modified Eagle's medium (HyClone, Logan, UT, USA) supplemented with 10% fetal bovine serum. The temperature and carbon dioxide concentration of the incubator were set at 37\(^\circ\)C and 5%, respectively [25].

**Cell proliferation assessment**

The cell counting kit-8 (CCK-8, Beyotime, Shanghai, China) was used to measure the inhibition rates of HaCaT, HeLa, C33A, and SiHa cell proliferation [26]. Single-cell suspensions were resuspended at a concentration of \(6 \times 10^4\) cells/ml after centrifugation (1000 rpm for 5 min). Single-cell suspensions (100 \(\mu\)L) were seeded in each well of a 96-well plate and incubated for 24 hours. The experimental design was as follows: six complexes per concentration, six concentration levels (0.16% DMSO, 20 \(\mu\)M, 40 \(\mu\)M, 80 \(\mu\)M, 120 \(\mu\)M, and 160 \(\mu\)M), and three test durations (24 hours, 48 hours, and 72 hours). GraphPad Prism was used to analyze the microplate reader (Thermo Fisher Scientific\textsuperscript{TM}, Madison, WI, USA) optical density values and to calculate the half maximal inhibitory concentration (IC50) and cell inhibition rates.

**Cell cycle assessment**

HeLa cells (1.2 \(\times\) 10\(^6\)) were equally seeded in four wells of a six-well plate and incubated for 24 hours. Four concentrations (0.16% DMSO, 20 \(\mu\)M, 80 \(\mu\)M, and 160 \(\mu\)M) of 6-methoxyflavone
were added to the HeLa cells and incubated for an additional 48 hours. A DNA content quantitation assay (Solarbio, Beijing, China) was used to detect the cell cycle. According to the instructions, 100 μL of RNase A solution and 400 μL of propidium iodide were added to each loading tube and incubated for 20 minutes at 4°C. A flow cytometer (Beckman Coulter, Fullerton, CA, USA) was used to record the fluorescence intensity at 488 nm. FlowJo 10.5.3 (TreeStar, Ashland, CA, USA) was used to calculate the fitting curve, and GraphPad Prism was used to analyze the percentage of HeLa cells in the different cell cycle phases [27].

Quantitative polymerase chain reaction

HeLa cells (8× 10^5) were seeded in two wells of a six-well plate and incubated for 24 hours. Two concentrations (0.16% DMSO and 65 μM) of 6-methoxyflavone were added, and the cells were incubated for an additional 48 hours. RNAiso plus reagent (Takara, Dalian, China) was added to each treated sample to extract total RNA. The PrimeScript™ RT and gDNA Eraser kit (Takara) was used to erase genomic DNA and synthesize complementary DNA. The TB Green® Premix Ex Taq™ II kit (Takara) and StepOnePlus real-time quantitative polymerase chain reaction (PCR) system (Thermo Fisher Scientific, Madison, WI, USA) were used to perform PCR. Glyceraldehyde 3-phosphate dehydrogenase (Sangon Biotech, Shanghai, China) was used as the internal reference. Finally, relative mRNA expression was calculated using the Livak method [24]. Primer sequences are listed in Table 1.

Western blot analysis

The HeLa cultivation and processing methods were the same as those used for PCR. Cell lysis buffer for western blotting and immunoprecipitation (Beyotime) and phenylmethanesulfonyl fluoride solution (Beyotime) were used to extract the protein samples. An enhanced bicinchoninic acid kit (Beyotime) was used to measure the protein concentration. Precontrast gels (4%-20%) (Beyotime) and polyvinylidene fluoride membranes (Merck Millipore, Burlington, VT, USA) were used for protein electrophoresis and transfer. The incubation times for 5% bovine albumin V, primary antibody, and secondary antibody were 1 hour, overnight, and 1.5 hours, respectively. The primary antibodies used were CCNA2, cyclin D1 (CCND1), cyclin E1 (CCNE1), cyclin dependent kinase 6 (CDK6), p21cip1 rabbit polyclonal antibody, CDK2 rabbit monoclonal antibody (1:1000, Beyotime) and glyceraldehyde 3-phosphate dehydrogenase rabbit polyclonal antibody (1:5000, Sangon Biotech). The Amersham Imager 680 system (GE Healthcare, Little Chalfont, UK) and a chemiluminescence kit (Beyotime) were used to generate grayscale images of the protein bands [28].

### Table 1. Primer sequences used for the quantitative polymerase chain reaction.

| Primer (human) | Forward | Reverse |
|----------------|---------|---------|
| CCNA2          | CGTGCGCAGTGACTGAATG | GAGGACGGTGACATGCTCAT |
| CCNB1          | AATAAGGCCGAGATGCAATG | TTTGTCAAGTGCCCACAGAAG |
| CCND1          | GCTGCAAGTGGAAACACATC | CCTCTCTGCAACATTTGAA |
| CCNE1          | AAGGAGGCGGACACCATG | ACGTCACGTTGGTTTCCC |
| CDK1           | AAACCTACAGTTCAAGTTGAGCC | TCTCTGATAAGCATACTCCTG |
| CDK2           | CCAGGATCTACTTATGCTTGA | TTACCTCAGGGAGGAACAC |
| CDK4           | ATGGCTACCTCTCGATGAGC | CATTGGGCACCTCACACTCT |
| CDK6           | GCTGACCAAGCGTACGAAAGT | GCACACATCAAACACCGGAC |
| P16Ink4A       | GATCCAGTGTCGAGGTAAGGTC | CCCCTCGAAACTCGTCT |
| p21cip1        | TGCGCTACAGAAACCATG | AAAGTCGAGTCATGCTTCC |
| TP53           | CACACATGAGCGGAGTTGT | TCTACCAAATACTCCAGCG |
| RB             | CTCTGCAGGCTTGAAGTTTG | GACATCTCATGAGGCTAG |

Abbreviations: CCNA2: cyclin A2; CCNB1: cyclin B1; CCND1: cyclin D1; CCNE1: cyclin E1; CDK1: cyclin-dependent kinase 1; CDK2: cyclin-dependent kinase 2; CDK6: cyclin-dependent kinase 6; P16Ink4A: p16 dependent kinase inhibitor 2A; p21cip1: p21cip1 cyclin-dependent kinase inhibitor 1A; TP53: tumor protein p53; RB: retinoblastoma transcriptional corepressor 1.
**Affinity and noncovalent interactions between 6-methoxyflavone and receptors**

The three-dimensional structure of 6-methoxyflavone was obtained from PubChem [12]. The crystal structures of CCNA2, CDK2, and p21CIP1 were obtained from the AlphaFold [29,30] database. The crystal structure of the complex between CCNA2 and CDK2 (2BKZ) [31] was downloaded from the Protein Data Bank (https://www.rcsb.org/). AutoDockTools (version 1.5.6) (http://autodock.scripps.edu/) was used to generate pdbqt format files, add hydrogen, and determine the active site. AutoDock Vina [32] was used to perform molecular docking and determine the binding free energy. The minimum free energy of each compound–receptor complex was converted to the inhibition constant (Ki)/dissociation constant (Kd). The ideal gas constant was 1.986 cal/K and the room temperature was 298 K (25°C).

PyMOL 2.2 (https://pymol.org/2/) was used to visualize the docking results. The PDB format files of the 6-methoxyflavone–receptor complexes were submitted to the Protein–Ligand Interaction Profiler [33] database. The noncovalent interactions and binding sites between 6-methoxyflavone and receptors were analyzed using the identifier function of the Protein–Ligand Interaction Profiler database.

**Analyses of clinical characteristics**

The drug sensitivity data of CCNA2, CCND1, CCNE1, CDK2, CDK2, and p21CIP1 were downloaded from the RNAactDrug database (http://bigdata.hrbmu.edu.cn/RNAactDrug/index.jsp). The data of six target expression levels and clinical characteristics of 304 cervical cancer samples were downloaded from The Cancer Genome Atlas. We divided the six targets into high-expression and low-expression groups according to the median. Disease free survival data was obtained from Gene Expression Profiling Interactive Analysis database [34]. GraphPad Prism software and Jvenn database were used to analyze and visualize the results.

**Statistical analysis**

GraphPad Prism was used for the statistical analysis. All experimental operations were performed for three biological replicates. All results were analyzed by a paired t test, one-way analysis of variance (ANOVA), or chi-square test. A nonlinear regression analysis was performed to calculate the IC50, and the log-rank test was performed for the survival analysis. Significant differences were indicated by p < 0.05.

**Results**

This study aimed to explore the molecular mechanisms of 6-methoxyflavone in HeLa cells. First, microarray analyses, transcriptome sequencing analyses, functional enrichment analyses, and gene set enrichment analyses were used to clarify the roles of 6-methoxyflavone in cervical cancer. Cell cycle assays, transcriptome sequencing, polymerase chain reactions, western blotting, molecular docking, and noncovalent interaction analyses were used to determine the molecular mechanism of 6-methoxyflavone in HeLa cells.

**Functional enrichment analysis and hub gene identification**

We obtained 178 targets of 6-methoxyflavone from the PharmMapper database. We identified 56 KEGG pathways, 200 biological processes, 32 cellular components, and 89 molecular functions in DAVID. Figure 1a shows the 10 most common KEGG pathway terms (p < 0.0001). 6-Methoxyflavone was mainly correlated with cancer-related pathways. The GO and KEGG enrichment analyses indicated that the targets were related to 15 KEGG cancer pathways (Figure 1b), eight cell proliferation biological processes (Figure 1c), six cell cycle terms (Figure 1d), and four drug terms (figure 1f) (p < 0.05). Figure 1e shows that the cell cycle terms were significantly enriched with 14 genes (p < 0.05). A principal component analysis of the 14 genes showed that 6-methoxyflavone was closely associated with five genes. The most important factor was CDK2 expression (Figure 1g).

We analyzed the mRNA expression data of 304 cervical cancer tissues and three healthy tissues.
Figure 1. Functional enrichment analyses of 178 targets. A. The 10 most common KEGG pathways (p < 0.0001). B. KEGG pathways related to cancer. C. Biological processes related to cell proliferation. D and F. Functional enrichment terms related to cell cycles and drugs (p < 0.05). E. Genes enriched in six cell cycle items. G. Principal component analysis of the genes enriched in the cell cycle. H. Intersections of the 178 targets and the DEmRNAs of cervical cancer. I. Intersections among the targets of the principal component analysis and DEmRNAs. Abbreviations: KEGG: Kyoto Encyclopedia of Genes and Genomes; DEmRNAs: differentially expressed mRNAs; FoxO: forkhead box O; PPAR: peroxisome proliferator activated receptor; CCNA2: cyclin A2; DHFR: dihydrofolate reductase; CHEK1: checkpoint kinase 1; EGFR: epidermal growth factor receptor; ADAM17: ADAM metallopeptidase domain 17; CDK2: cyclin-dependent kinase 2; CDK6: cyclin dependent kinase 6; CDK7: cyclin-dependent kinase 7; GSK3B: glycogen synthase kinase 3 beta; TGFβ2: transforming growth factor beta 2; EIF4E: eukaryotic translation initiation factor 4E; PIM1: Pim-1 proto-oncogene, serine/threonine kinase; FGFR1: fibroblast growth factor receptor 1; FGFR2: fibroblast growth factor receptor 2.
A total of 3745 mRNAs were identified as DEmRNAs. The intersections among the 178 targets and 3745 DEmRNAs are shown in Figure 1h. Of the 178 targets, 24.7% were cervical cancer DEmRNAs. Two genes (CCNA2 and CDK2) showed overlaps between the principal component analysis data and DEmRNA data (Figure 1i). CCNA2 and CDK2 are highly expressed in cervical cancer.

**Gene set enrichment analysis**

The 18,013 mRNA expression profiles of 304 cervical cancer samples were obtained from The Cancer Genome Atlas. Overall, 308 biological processes and 9 KEGG pathways were enriched in the high-CCNA2 expression group, whereas 153 biological processes and eight KEGG pathways were enriched in the high CDK2 expression group (q < 0.01). Figure 2a shows the five terms with the highest normalized enrichment scores for each dataset. Figure 2b shows that the highest normalized enrichment scores terms in these four datasets were chromosome segregation, cell cycle, DNA replication, and cell cycle. It is unclear whether chromosome segregation and DNA replication are involved in cell cycle progression. Enrichment scores were greater than zero. The results indicated that high CCNA2 expression and high CDK2 expression promoted cell cycle progression in cervical cancer.

**6-Methoxyflavone was significantly related to the cell cycle or proliferation**

To elucidate the anticancer effects of 6-methoxyflavone, we used eukaryotic transcriptome sequencing to identify significantly enriched biological processes and KEGG pathways in human HeLa cells treated with 6-methoxyflavone. High-throughput sequencing data quality control results showed that all six samples were of acceptable quality and were free from contamination (Supplement Tables S1 and S2). Compared with the three 0.16% DMSO-treated control samples, a total of 2894 significantly differentially expressed transcripts in the three samples treated with 65 μM 6-methoxyflavone were observed. Among these 2894 transcripts, 1264 were upregulated and 1630 were downregulated (Figure 3a). Figure 3b shows the 10 most common KEGG pathways significantly enriched by 6-methoxyflavonoid (p < 0.05), 6-Methoxyflavonoid was significantly associated with pathways in cancer and viral carcinogenesis. We obtained 181
significantly enriched biological processes using GO analysis. 6-Methoxyflavone was significantly related to the 15 cell cycle biological processes (Figure 3c) and seven cell proliferation (Figure 3d) biological processes (p < 0.05).

6-Methoxyflavone inhibited cell proliferation
A functional enrichment analysis of the 178 targets showed that 6-methoxyflavone was closely related to pathways related to cancer and cell proliferation. Therefore, a CCK-8 kit was used to detect the
inhibitory effects of 6-methoxyflavone on cervical cancer cells. First, we treated HaCaT, C33A, SiHa, and HeLa cells at six concentrations (0.16% DMSO, 20 μM, 40 μM, 80 μM, 120 μM, and 160 μM) of 6-methoxyflavone for 48 hours. We compared C33A, SiHa, and HeLa cell inhibition with HaCaT cell inhibition and found that the difference between HeLa and HaCaT cells was the most significant (Figure 4a). HeLa cells were most sensitive to 6-methoxyflavone, which is consistent with the results of a previous study [9]. Next, we treated HeLa cells with six concentrations of 6-methoxyflavone for 24 hours, 48 hours, and 72 hours. The IC50 values of 24 hours, 48 hours, and 72 hours were 94.05 μM, 62.24 μM, and 52.12 μM, respectively. Compared with 24 hours, the inhibition rates at 48 hours and 72 hours were significantly higher. However, there were no significant differences between 48 hours and 72 hours at concentrations of 80 μM, 120 μM, and 160 μM (Figure 4b). Therefore, we treated HeLa cells with 65 μM 6-methoxyflavone for 48 hours during subsequent PCR and western blot analyses.

**6-Methoxyflavone induced HeLa cell S-phase arrest**

We detected the percentages of the different cell cycle phases and found that as the concentration of 6-methoxyflavone increased, the percentage of S-phase cells increased and the G2/M phase was
reversed. 6-Methoxyflavone significantly increased the percentage of S-phase cells in a concentration-dependent manner. These findings indicate that 6-methoxyflavone significantly induced S-phase arrest in HeLa cells (Figure 4c, D).

Because the results of the cell cycle assessment showed that 6-methoxyflavone induced S-phase arrest in HeLa cells, we next explored whether 6-methoxyflavone affected the relative mRNA and protein expression levels in the cell cycle pathway.

The relative mRNA and protein expression levels of CCNA2 and CDK2 in the 6-methoxyflavone treatment group (65 μM) were significantly lower than those of the control group (0.16% DMSO), however, the mRNA and protein expression levels of CCND1, CCNE1, CDK6, and p21CIP1 were significantly higher (Figure 5). However, mRNA expression levels of cyclin B1 (CCNB1), cyclin-dependent kinase 1 (CDK1), cyclin-dependent kinase 4 (CDK4), cyclin dependent kinase inhibitor 2A (P16INK4), tumor

![Figure 5. 6-Methoxyflavone induces S-phase arrest through the CCNA2/CDK2/p21CIP1 pathway. HeLa cells were treated with 6-methoxyflavone (0.16% DMSO and 65 μM) for 48 hours. Cell cycle-related mRNA and protein expression were measured by PCR and western blotting. A. The relative mRNA expressions of CCNA2, CCNB1, CCND1, CCNE1, CDK1, CDK2, CDK4, CDK6, P16INK4, p21CIP1, TP53, and RB. B and C. Protein expressions of CCNA2, CCND1, CCNE1, CDK2, CDK6, and p21CIP1. Each assay was performed in triplicate. Statistical analysis was performed using the paired t-test. *p < 0.05. **p < 0.01. n.s.: not significant. Abbreviations: CCNA2: cyclin A2; CCNB1: cyclin B1; CCND1: cyclin D1; CCNE1: cyclin E1; CDK1: cyclin-dependent kinase 1; CDK2: cyclin-dependent kinase 2; CDK4: cyclin-dependent kinase 4; CDK6: cyclin-dependent kinase 6; P16INK4: cyclin dependent kinase inhibitor 2A; p21CIP1: cyclin-dependent kinase inhibitor 1A; TP53: tumor protein p53; RB: retinoblastoma transcriptional corepressor 1.]

| GeneName  | GeneID       | Transcript id | log2FoldChange | qValue |
|-----------|--------------|---------------|----------------|--------|
| CCNA2     | ENSG00000145386 | ENST00000618014 | -0.8277      | 0.0003 |
| CCND1     | ENSG00000110092 | ENST00000227507 | 0.8394       | 2.66E-11 |
| CCNE1     | ENSG00000105173 | ENST00000357943 | 0.6317       | 0.8789 |
| CDK2      | ENSG00000123374 | ENST00000554619 | -1.3566      | 0.0358 |
| CDK6      | ENSG00000105810 | ENST00000265734 | 1.0095       | 0.0247 |
| p21CIP1   | ENSG00000124762 | ENST00000615513 | 1.2123       | 0.0058 |

Abbreviations: CCNA2: cyclin A2; CCND1: cyclin D1; CCNE1: cyclin E1; CDK2: cyclin-dependent kinase 2; CDK6: cyclin dependent kinase 6; p21CIP1: cyclin-dependent kinase inhibitor 1A.
protein p53 (TP53), and retinoblastoma transcriptional corepressor 1 (RB) were not significantly affected by 6-methoxyflavone (Figure 5a). The PCR and western blot results indicated that 6-methoxyflavone induced S-phase arrest via the cyclin A2 (CCNA2)/CDK2/p21CIP1 pathway. Each phase of the cell cycle contributed to the entire cycle. The mRNA expression levels of CCND1, CCNE1 and CDK6 were affected by 6-methoxyflavone. These mRNA expression levels were consistent with the results of transcriptome sequencing (Table 2).

**Affinity and noncovalent interactions between 6-methoxyflavone and receptors**

The minimum free energy levels between 6-methoxyflavone and CCNA2, CDK2, p21CIP1, and the CCNA2–CDK2 complex were −7.1 kcal/M, −8.6 kcal/M, −6.2 kcal/M, and −8.8 kcal/M, respectively (Figure 6a, C; Table 3). The corresponding Ki/Kd values were 6.16 μM, 0.49 μM, 28.2 μM, and 0.35 μM (Table 3). In this pathway, 6-methoxyflavone had the strongest affinity toward and inhibitory effects on CDK2. The combination of CDK2
and CCNA2 enhanced these effects. The noncovalent interactions between 6-methoxyflavone and the receptors consisted of seven (CCNA2) or 11 (CDK2) hydrophobic interactions, one (CDK2) or two (CCNA2–CDK2 complex) hydrogen bonds, and three salt bridges (CCNA2–CDK2 complex) (Figure 6b, D, E). In contrast, there were no noncovalent interactions between 6-methoxyflavone and p21CIP1.

**Clinical characteristic analysis**

Functional enrichment analyses showed that the targets were related to the four drug terms (Figure 1f) (p < 0.05). Therefore, we downloaded the drug sensitivity data of six receptors from RNAactDrug. CCNA2, CCND1, CCNE1, CDK2, CDK6, and p21CIP1 were related to 137, 228, 75, 179, 151, and 23 drugs, respectively (p < 0.05) (Figure 7a). Then, we performed a secondary screening of the data by applying p < 0.05. We set the filter condition as |Pearson and Spearman correlation coefficients| ≥ 0.4. The expression levels of CCNA2, CCND1, CDK2 and CDK6 were closely associated with six drugs, 23 drugs, and one drug, respectively (Figure 7a, B). 6-Methoxyflavone may regulate the sensitivity of other drugs. Survival analyses of the six receptors showed that the survival rates of the high CCND1 expression and low CCND1 expression groups were significantly different (p < 0.05) (Figure 7c). The five-year to 10-year overall survival rates of the high p21CIP1 expression and low p21CIP1 expression groups were significantly different (p < 0.05) (Figure 7d). Disease free survival rates in the low CCNA2 expression and low CDK2 expression groups were higher than corresponding high-expression groups (Figure 7e, F). The mRNA expression levels of CCND1, CCNE1, CDK2, CDK6, and p21CIP1 were significantly related to the histological classification of cervical cancer (p < 0.05). The mRNA expression levels of CDK2, CDK6, and p21CIP1 were significantly related to the age, primary tumor, and Federation International of Gynecology and Obstetrics stage of the patients (p < 0.05) (Table 4).

**Discussion**

Natural products have become an important adjuvant therapy for cancer and are an effective way of preventing chemoresistance [35]. Cell and animal experiments indicated that glycyrrhizic acid, quercetin, and homoharringtonine exhibited strong anticancer activity in colon and colorectal cancer progression by inhibiting sirtuin 3, phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), and PI3K/AKT/mechanistic target of rapamycin kinase (mTOR) signaling pathways [36–38].

In vivo and in vitro experiments related to breast cancer have shown that Imperatae rhizoma extract inhibited cell viability and tumor growth [39]. 6-Methoxyflavone is an important active ingredient in Imperatae rhizoma. A HeLa cell proliferation assessment also indicated that 6-methoxyflavone has anticancer activity [9]. However, the specific anticancer mechanism of 6-methoxyflavone has not yet been elucidated. During this study, we identified 178 putative targets of 6-methoxyflavone. Functional enrichment analyses of the targets and transcriptome sequencing results indicated that 6-methoxyflavone was significantly related to cancer, cell proliferation, and the cell cycle (p < 0.05). We identified intersections between two highly expressed genes (CCNA2 and CDK2) for five cell cycle principal component analysis targets and 3745 DEmRNAs. The gene set enrichment analysis results of CCNA2 and

---

**Table 3. Molecular docking parameters of 6-methoxyflavone and receptors.**

| Targets     | Ligand | Interactions                | Minimum binding affinity (kcal/M) | Ki/Kd values (μM) | Distance/Bond length (Å) |
|-------------|--------|-----------------------------|-----------------------------------|-------------------|-------------------------|
| CCNA2       | 6MF    | Hydrophobic Interactions    | −7.1                              | 6.16              | 2.49                    |
| CDK2        | 6MF    | Hydrophobic Interactions    | −8.6                              | 0.49              | 2.30                    |
| CDK2        | 6MF    | Hydrogen Bonds              | −8.6                              | 0.49              | 2.73                    |
| CCNA2_CDK2  | 6MF    | Hydrogen Bonds              | −8.8                              | 0.35              | 3.625                   |
| CCNA2_CDK2  | 6MF    | Salt Bridge                 | −8.8                              | 0.35              | 4.20                    |

Abbreviations: Ki: inhibition constant; Kd: dissociation constant; 6MF: 6-Methoxyflavone
CDK2 indicated that high mRNA expressions of CCNA2 and CDK2 stimulate cell cycle progression in cervical cancer. Compared with a series of studies of colon cancer and colorectal cancer, this study also evaluated molecular docking and non-covalent interactions between 6-methoxyflavone and receptors.

Cyclins and cyclin-dependent kinases have an important role in cell cycle regulation and cell proliferation. Overexpression of Roundabout homolog 1 caused S-phase arrest to inhibit pancreatic cancer cell proliferation by significantly reducing the expressions of CCNA2 and CDK2 [40]. Cyclin B2 (CCNB2) knockdown significantly suppressed cell proliferation and induced G2/M-phase arrest in acute myeloid leukemia cells [41]. Suppression of cell division cycle-associated 3 induced G0/G1-phase arrest to inhibit prostate cancer cell proliferation via cyclin D1 signaling inactivation and p21CIP1 accumulation [42]. Silencing of tumor susceptibility 101 reduced proliferation and induced G0/G1 arrest by markedly decreasing the expression of cyclin E1/CDK2 in renal cell carcinoma [43]. The S phase is an important process in DNA replication and synthesis during the cell cycle. S-phase arrest results in failures in DNA replication, mitosis [44], cell growth, and proliferation [45–47]. The cyclin/cyclin-dependent kinase (CDK)/CDK inhibitor (CKI) network is the core regulatory pathway of the cell cycle. The CCNA1/CCNB1/CDK1/p21CIP1 pathway is associated with G2/M-phase arrest in glioblastoma cells [48]. The CCNB/CDK/cyclin dependent kinase inhibitor 1B pathway was confirmed to be related to cell cycle progression in prostate cancer [49]. The cyclin/CDK1/CKI pathway was found to affect cell cycle distribution and proliferation of human oral squamous cell carcinoma cells [50]. During this study, we found that 6-methoxyflavone inhibited proliferation and induced S-phase arrest through the CCNA2/CDK2/p21CIP1 signaling pathway in HeLa cells.
Table 4. Relationships between mRNA expression levels of six targets and the clinicopathological parameters of cervical cancer patients.

| Parameters                  | Relative expression of CCNA2 | Relative expression of CCND1 | Relative expression of CCNE1 | Relative expression of CDK2 | Relative expression of CDK6 | Relative expression of p21CIP1 |
|-----------------------------|------------------------------|------------------------------|-----------------------------|------------------------------|------------------------------|------------------------------|
| Age (n = 304)               |                              |                              |                             |                              |                              |                              |
| ≥60 years old               | 34 31                        | 0.67                         | 33 32                       | 0.89                         | 31 34                       | 0.67                         |
| <60 years old               | 118 121                      | 119 120                      | 121 118                     | 127 112                     | 125 114                     | 119 120                     |
| Histological classification |                              |                              |                             |                              |                              |                              |
| (n = 304)                   |                              |                              |                             |                              |                              |                              |
| Squamous cell cancer        | 130 122                      | 0.22                         | 133 119                     | 0.03*                        | 133 119                     | 0.03*                        |
| Adenocarcinoma              | 22 30                        | 0.30                         | 19 33                       | 15 37                        | 146 106                     | <0.01**                      |
| Primary tumor               |                              |                              |                             |                              |                              |                              |
| (n = 241)                   |                              |                              |                             |                              |                              |                              |
| T1-T2                       | 102 109                      | 0.86                         | 96 115                      | 0.14                         | 104 107                     | 0.45                         |
| T3-T4                       | 15 15                        | 18 12                        | 17 13                       | 15 15                        | 96 115                      | 0.94                         |
| Lymph node invasion         |                              |                              |                             |                              |                              |                              |
| (n = 193)                   |                              |                              |                             |                              |                              |                              |
| N0                          | 64 69                        | 0.65                         | 61 72                       | 0.59                         | 56 70                       | 0.93                         |
| N1                          | 31 29                        | 0.30                         | 30 30                       | 0.28                         | 28 32                       | 0.32                         |
| FIGO stage (n = 297)        |                              |                              |                             |                              |                              |                              |
| Stage I–II                  | 112 119                      | 0.28                         | 113 118                     | 0.71                         | 113 118                     | 0.56                         |
| Stage III–IV                | 37 29                        | 0.32                         | 34 32                       | 0.35                         | 35 31                       | 0.36                         |
| Statistical analyses were performed using the chi-square test. *p < 0.05, **p < 0.01. Abbreviations: FIGO: Federation International of Gynecology and Obstetrics. 

The purpose of all basic medical experimental research is to improve the clinical status of patients. The clinical characteristic analysis results showed that 6-methoxyflavone might be related to clinicopathological parameters (drug sensitivity, survival rate, histological classification, age, primary tumor, and Federation International of Gynecology and Obstetrics stage stage) of cervical cancer patients. Therefore, 6-methoxyflavone could be a possible treatment for cervical cancer.

**Conclusion**

During this study, we explored the effect of 6-methoxyflavone on HaCaT, SiHa, C33A, and HeLa cells using a CCK-8 kit and a cell cycle assay. The results revealed that 6-methoxyflavone inhibited HaCaT, SiHa, C33A, and HeLa cell proliferation and induced S-phase arrest in HeLa cells. Moreover, PCR and western blot results showed that 6-methoxyflavone induced S-phase arrest via the CCNA2/CDK2/p21CIP1 pathway. The CCNA2/CDK2/p21CIP1 pathway is the most critical molecular factor in S-phase regulation. The molecular docking and noncovalent interaction analysis results showed that 6-methoxyflavone had the strongest affinity toward, inhibitory effect on, and noncovalent interactions with CDK2, and the combination of CDK2 and CCNA2 enhanced these effects.

The clinical characteristic analyses showed that 6-methoxyflavone might be related to six clinicopathological parameters of cervical cancer patients. 6-Methoxyflavone could be a possible treatment for cervical cancer.

**Acknowledgments**

The study was supported by the Key Laboratory of Gynecological Oncology of Gansu Province of China (18JR2RA022), the Natural Science Foundation of Gansu Province of China (20JR10RA693) and by the Project of Administration of Traditional Chinese Medicine of Gansu Province of China (GZKG-2020-46).

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Funding**

The author(s) reported there is no funding associated with the work featured in this article.
References

[1] van der Horst J, Siebers AG, Bulten J, et al. Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004–2013. Cancer Med. 2017;6(2):416–423.

[2] Xiao Y, Liang M-R, Liu -C-C, et al. Overexpression of P16 reversed the MDR1-mediated DDP resistance in the cervical adenocarcinoma by activating the ERK1/2 signaling pathway. Cell Division. 2019;14(1):6.

[3] Jung EJ, Byun JM, Kim YN, et al. Cervical adenocarcinoma has a poorer prognosis and a higher propensity for distant recurrence than squamous cell carcinoma. Int J Gynecol Cancer. 2017;27(6):1228–1236.

[4] Yanaranop M, Sathaporntheera N, Nakrangsee S. Risk factors of pelvic lymph node metastasis in cervical adenocarcinoma following radical hysterectomy and pelvic lymphadenectomy. J Med Assoc Thai. 2014;97 Suppl 11(11):S87–95. PMID: 25509701.

[5] Lu H, Chen H, Liu Y, et al. Clinical analysis of ovarian metastasis in patients with Ib stage cervical adenocarcinoma. Zhonghua Yi Xue Za Zhi. 2016;96(3):203–206.

[6] Tong J, Yu H, Li J, et al. Short-term recurrence and distant metastasis following robotic-assisted radical hysterectomy with pelvic lymphadenectomy and chemoradiotherapy for a stage IB1 cervical adenocarcinoma: a case report and literature review. Medicine (Baltimore). 2019;98(17):e15387.

[7] Hall BJ, Karim N, Chebib M, et al. Modulation of ionotropic GABA receptors by 6-methoxyflavonone and 6-methoxyflavone. Neurochem Res. 2014;39 (6):1068–1078.

[8] So J-S, Kim G-C, Song M, et al. 6-methoxyflavone inhibits NFAT translocation into the nucleus and suppresses T cell activation. The Journal of Immunology. 2014;193(6):2772–2783.

[9] Kinjo J, Nakano D, Fujioka T, et al. Screening of promising chemotherapeutic candidates from plants extracts. J Nat Med. 2016;70(3):335–360.

[10] Shahid M, Subhan F, Ahmad N, et al. The flavonoid 6-methoxyflavone allays cisplatin-induced neuropathic alldynia and hypoalgesia. Biomed Pharmacother. 2017;95:1725–1733.

[11] Wang X, Wang ZW, Sidhu PS, et al. 6-hydroxyflavone and derivatives exhibit potent anti-inflammatory activity among mono-, di- and polyhydroxylated flavones in kidney mesangial cells. Plos One. 2015;10. DOI:10.1371/journal.pone.0116409.

[12] Kim S, Chen J, Cheng T, et al. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 2021;49(D1):D1388–D95.

[13] Liu X, Ouyang S, Yu B, et al. PharmMapper server: a web server for potential drug target identification using pharmaphore mapping approach. Nucleic Acids Res. 2010;38(suppl_2):W609–14.

[14] Wang X, Pan C, Gong J, et al. Enhancing the enrichment of pharmaphore-based target prediction for the polypharmacological profiles of drugs. J Chem Inf Model. 2016;56(6):1175–1183.

[15] Wang X, Shen Y, Wang S, et al. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmaphore database. Nucleic Acids Res. 2017;45(W1):W356–W60.

[16] Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.

[17] Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1–13.

[18] Walter W, Sánchez-Cabo F, Ricote M. GOplot: an R package for visually combining expression data with functional analysis: fig. 1. Bioinformatics. 2015;31(17):2912–2914.

[19] Bardou P, Mariette J, Escudié F, et al. jvenn: an interactive Venn diagram viewer. BMC Bioinformatics. 2014;15(1):293.

[20] Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–140.

[21] Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550.

[22] Mootha VK, Lindgren CM, Eriksson K-F, et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267–273.

[23] Wickham H. ggplot2 elegant graphics for data analysis introduction. Use R. 2009;1. DOI:10.1007/978-0-387-98141-3_1

[24] Tao X, Cheng J, Wang X. Effect of miRNA-200a on radiosensitivity of osteosarcoma cells by targeting bone morphogenetic protein receptor 2. Bioengineered. 2021;12(2):12625–12635.

[25] Cheng C, Zhang H, Dai Z, et al. Circular RNA circVRK1 suppresses the proliferation, migration and invasion of osteosarcoma cells by regulating zinc finger protein ZNF652 expression via microRNA miR-337-3p. Bioengineered. 2021;12(1):5411–5427.

[26] Tang G, Liu L, Xiao Z, et al. CircRAB3IP upregulates twist family BHLH transcription factor (TWIST1) to promote osteosarcoma progression by sponging miR-580-3p. Bioengineered. 2021;12(1):3385–3397.
[27] Zhang N, Zhang Y, Wu B, et al. Role of WW domain E3 ubiquitin protein ligase 2 in modulating ubiquitination and degradation of Septin4 in oxidative stress endothelial injury. Redox Biol. 2020;30:101419.

[28] Zhang Q, Wang L, Cao L, et al. Novel circular RNA circATRNL1 accelerates the osteosarcoma aerobic glycolysis through targeting miR-409-3p/LDHA. Bioengineered. 2021;12(2):9965–9975.

[29] Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583–589.

[30] Tunyasuvunakool K, Adler J, Wu Z, et al. Highly accurate protein structure prediction for the human proteome. Nature. 2021;596(7873):590–596.

[31] D'Alessio R, Bargiotti A, Metz S, et al. Benzodipyrazoles: a new class of potent CDK2 inhibitors. Bioorg Med Chem Lett. 2005;15 (5):1315–1319.

[32] Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–461.

[33] Adasme MF, Linnemann KL, Bolz SN, et al. PLIP 2021: expanding the scope of the protein–ligand interaction profiler to DNA and RNA. Nucleic Acids Res. 2021;49 (W1):W530–w4.

[34] Tang ZF, Li CW, Kang BX, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–w102.

[35] Yuan R, Hou Y, Sun W, et al. Natural products to prevent drug resistance in cancer chemotherapy: a review. Ann N Y Acad Sci. 2017;1401(1):19–27.

[36] Zuo Z, He L, Duan X, et al. Glycyrrhizic acid exhibits strong anticancer activity in colorectal cancer cells via SIRT3 inhibition. Bioengineered. 2022;13 (2):2720–2731.

[37] Na S, Ying L, Jun C, et al. Study on the molecular mechanism of nightshade in the treatment of colon cancer. Bioengineered. 2022;13(1):1575–1589.

[38] Qu M, Li J, Yuan L. Uncovering the action mechanism of homoharringtonine against colorectal cancer by using network pharmacology and experimental evaluation. Bioengineered. 2021;12(2):12940–12953.

[39] Li Y, Li X, Cuiping C, et al. Study on the Anticancer Effect of an Astragaloside- and Chlorogenic Acid-Containing Herbal Medicine (RLT-03) in Breast Cancer. Evid Based Complement Alternat Med. 2020;2020:1515081.

[40] Chen Q, Shen P, Ge W-L, et al. Roundabout homolog 1 inhibits proliferation via the YY1-ROBO1-CCNA2-CDK2 axis in human pancreatic cancer. Oncogene. 2021;40(15):2772–2784.

[41] Li H, Tian X, Wang P, et al. MicroRNA-582–3p negatively regulates cell proliferation and cell cycle progression in acute myeloid leukemia by targeting cyclin B2. Cell Mol Biol Lett. 2019;24(1):66.

[42] Gu P, Zhang M, Zhu J, et al. Suppression of CDCA3 inhibits prostate cancer progression via NF-κB/cyclin D1 signaling inactivation and p21 accumulation. Oncol Rep. 2022;47(2). DOI:10.3892/or.2021.8253.

[43] Xu C, Zheng J. siRNA against TSG101 reduces proliferation and induces G0/G1 arrest in renal cell carcinoma – involvement of c-myc, cyclin E1, and CDK2. Cell Mol Biol Lett. 2019;24(1):7.

[44] Sozmen M, Tunca R, Dag Erginsoy S. Cyclin A expression is associated with apoptosis and mitosis in murine 3-methylcholanthrene-induced fibrosarcomas. Exp Toxicol Pathol. 2009;61(1):41–49.

[45] He K, He J, Wang S, et al. hSHIP induces S-phase arrest and growth inhibition in cervical cancer HeLa cells. J Genet Genomics. 2010;37(4):249–255.

[46] Li Y-L, Gan X-L, Zhu R-P, et al. Anticancer activity of platinum (II) Complex with 2-benzoylpyridine by induction of DNA damage, S-phase arrest, and apoptosis. Anticancer Agents Med Chem. 2020;20 (4):504–517.

[47] Liu Z, Liu L, Sun R, et al. BAF45D knockdown decreases cell viability, inhibits colony formation, induces cell apoptosis and S-phase arrest in human pancreatic cancer cells. Biosci Biotechnol Biochem. 2020;84(6):1146–1152.

[48] Shendge AK, Chaudhuri D, Mandal N. The natural flavones, acacetin and apigenin, induce Cdk-Cyclin mediated G2/M phase arrest and trigger ROS-mediated apoptosis in glioblastoma cells. Mol Biol Rep. 2021;48(1):539–549.

[49] Wedel S, Hudak L, Seibel J-M, et al. Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis. BMC Cancer. 2011;11 (1):375.

[50] Fu X-J, Li H-X, Yang K, et al. The important tumor suppressor role of PER1 in regulating the cyclin-CDK-CKI network in SCC15 human oral squamous cell carcinoma cells. Onco Targets Ther. 2016;9:2237–2245.